hexenoyl cap raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
=== Distribution === Strychnine is transported by plasma and red blood cells. Due to slight protein binding, strychnine leaves the bloodstream quickly and distributes to bodily tissues. Approximately 50% of the ingested dose can enter the tissues in 5 minutes. Also within a few minutes of ingestion, strychnine can be detected in the urine. Little difference was noted between oral and intramuscular administration of strychnine in a 4 mg dose. In persons killed by strychnine, the highest concentrations are found in the blood, liver, kidney and stomach wall. The usual fatal dose is 60–100 mg strychnine and is fatal after a period of 1–2 hours, though lethal doses vary depending on the individual.
=== Oxygen therapy === Oxygen therapy at home is recommended in those with significantly low oxygen levels. Oxygen therapy in ILD is associated with improvements in quality of life but reductions in mortality are uncertain. Long-term oxygen therapy can be beneficial to people with ILD and hypoxemia to enhance gas exchange, lessen dyspnea, and increase physical activity.
== Chemistry == Amino acid sequence: Asp-Cys-Val-Arg-Phe-Trp-Gly-Lys-Cys-Ser-Gln-Thr-Ser-Asp-Cys-Cys-Pro-His-Leu-Ala-Cys-Lys-Ser-Lys-Trp-Pro-Arg-Asn-Ile-Cys-Val-Trp-Asp-Gly-Ser-Val Molecular formula: C177H268N52O50S6 ω-Grammotoxin SIA can be purified from Grammostola rosea venom by reverse phase high performance liquid chromatography.
Estimating the daily requirement for the indispensable amino acids has proven to be difficult; these numbers have undergone considerable revision over the last 20 years. The following table lists the recommended daily amounts currently in use for essential amino acids in adult humans (unless specified otherwise), together with their standard one-letter abbreviations.
Sources: en.wikipedia.org
=== Femarelle Unstoppable === Femarelle Unstoppable is designed for postmenopausal women, with a focus on bone health, muscle function, and overall wellbeing during later stages of menopause. The formulation contains DT56a, calcium, vitamin D3, biotin, and riboflavin (vitamin B2).
=== Molar mass of cellulose === In the pulp and paper industry, molar mass is traditionally measured with a method where the intrinsic viscosity (dL/g) of the pulp sample is measured in cupriethylenediamine (Cuen). The intrinsic viscosity [η] is related to the weight-average molar mass (in daltons) by the Mark–Houwink equation: [η] = 0.070 Mw0.70. However, it is typical to cite [η] values directly in dL/g, as the "viscosity" of the cellulose, confusingly as it is not a viscosity.
=== Glycolysis === Glycolysis is the process of breaking down a glucose molecule into two pyruvate molecules, while storing energy released during this process as adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NADH). Nearly all organisms that break down glucose utilize glycolysis. Glucose regulation and product use are the primary categories in which these pathways differ between organisms. In some tissues and organisms, glycolysis is the sole method of energy production. This pathway is common to both anaerobic and aerobic respiration. Glycolysis consists of ten steps, split into two phases. During the first phase, it requires the breakdown of two ATP molecules. During the second phase, chemical energy from the intermediates is transferred into ATP and NADH. The breakdown of one molecule of glucose results in two molecules of pyruvate, which can be further oxidized to access more energy in later processes. Glycolysis can be regulated at different steps of the process through feedback regulation. The step that is regulated the most is the third step. This regulation is to ensure that the body is not over-producing pyruvate molecules. The regulation also allows for the storage of glucose molecules into fatty acids. There are various enzymes that are used throughout glycolysis. The enzymes upregulate, downregulate, and feedback regulate the process.
People need to have a driving licence to drive on a road, and there is a common system of recognition around the EU. For delivery vehicle workers, the Road Transport Regulation 2006 limits daily driving time to 9 hours a day, a maximum of 56 hours a week, and requires at least a 45-minute break after 4+1⁄2 hours. Drivers may also not be paid according to distance travelled if this would endanger road safety. Taxi enterprises are usually regulated separately in each member state, and the attempts of the app-based firm Uber to evade regulation by arguing it was not a "transport service" rather than an "Information Society Service" failed. Most bus networks are publicly owned or procured, but there are common rights. If buses are delayed in journeys over 250 kilometres, the Bus Passenger Rights Regulation 2011 entitles passengers to compensation. Under article 19, a delay over two hours must result in compensation of 50% of the ticket price, as well as rerouting and reimbursement. Article 6 says 'Carriers may offer contract conditions that are more favourable for the passenger', although it is not clear many take up this option. Article 7 says member states cannot set maximum compensation for death or injury lower than €220,000 per passenger or €1200 per item of luggage. There is not yet a requirement for the major bus, delivery, taxi enterprises to electrify their fleets even though this would create the fastest reduction of emissions and would be cheaper for business in total operating costs.
== Gottron's sign == Gottron's sign is erythematous or violaceous macules or plaques overlying the elbows and/or knees, and it is considered a less specific finding for DM. The macules or plaques follow the same symmetric distribution pattern as Gottron's papules but do not appear in the interphalangeal spaces. This is a contrasting dermatologic distribution pattern to what is observed in patients with systemic lupus erythematosus.
Sources: en.wikipedia.org
=== Metabolic === Cachexia can also result from changes in metabolism. Tumors sometimes release molecules that break down fat and muscle, causing cachexia by making it harder for the body to keep up with energy needs. These molecules include lipid mobilizing factor, proteolysis-inducing factor, and mitochondrial uncoupling proteins. In addition, uncontrolled inflammation in people with cachexia increases the body's need for nutrients. The way the body uses nutrients is also changed in cachexia. People with cachexia can have loss of appetite, are less responsive to insulin, and can have increased fat breakdown, all of which make it difficult for the body to properly use food. This is especially true in people with cancer.
Siddhartha Gautama was said to have been a "mahapurisa" (great man) who could have chosen to become a wheel turning king, but instead became the spiritual counterpart to such a king, a wheel turning sage, that is, a Buddha. In his explanation of the term "turning the wheel of Dharma", the Theravada exegete Buddhaghosa explains that this "wheel" which the Buddha turned is primarily to be understood as wisdom, knowledge, and insight (ñāṇa). This wisdom has two aspects, paṭivedha-ñāṇa, the wisdom of self-realisation of the Truth and desanā-ñāṇa, the wisdom of proclamation of the Truth. The dharmachakra symbol also points to the central Indian idea of "Dharma", a complex and multivalent term which refers to the eternal cosmic law, universal moral order and in Buddhism, the very teaching and path expounded by the Buddha. In Buddhist art at early sites such as Bharhut and Sanchi, the dharmachakra was often used as a symbol of Gautama Buddha himself. The symbol is often paired with the triratna (triple jewel) or trishula (trident) symbolizing the triple gem, umbrellas (chatra), symbols of sovereignty and royal power, gems and garlands. It is also sometimes depicted alongside animals such as lions, or deer. There are different designs of the Buddhist dharmachakra with 8, 12, 24 or more spokes. In different Buddhist traditions, the different number of spokes may represent different aspects of the Buddha's Dharma (teaching).
=== Effects on longitudinal bone growth === Cilostazol has been investigated in preclinical models as a stimulator of endochondral bone growth. PDE3 is expressed in proliferating chondrocytes of the growth plate, and that Pde3b-knockout mice show enlargement of the tibia and other long bones. In embryonic mouse metatarsal explant cultures, cilostazol at 10 μM increased longitudinal outgrowth over four days, expanding the round and columnar chondrocyte zones and increasing alcian-blue-stained extracellular matrix; the PDE3 inhibitors milrinone, anagrelide and olprinone produced comparable effects, while inhibitors selective for PDE2 or PDE10 did not. When three-week-old C57BL/6 mice received daily intraperitoneal injections of cilostazol at 10 mg/kg for four weeks, naso-anal body length was significantly greater than in vehicle-treated controls, and a similar growth-promoting effect was observed in Fgfr3-transgenic mice, a model of achondroplasia. Mechanistically, the authors proposed that PDE3 inhibition raises intracellular cyclic GMP in growth-plate chondrocytes — cilostazol-treated bones showed an approximately 1.7-fold increase in cGMP — activating protein kinase G, which phosphorylates plasma-membrane potassium channels. The resulting membrane hyperpolarisation is thought to enhance the driving force for TRPM7-mediated Ca²⁺ entry and thereby stimulate cartilage matrix synthesis, converging on the C-type natriuretic peptide (CNP) signalling axis targeted clinically by vosoritide.
Looksmaxxing has been connected to incel sub-culture since its origins within it. Writing for The Conversation, senior lecturer and researcher Jamilla Rosdahl of the Australian College of Applied Psychology considers that the practice converts young men into incels, as a result of TikTok algorithms. On the popularity of looksmaxxing amongst young people overall, she wrote that "where young people feel like they can't control their environment, they may turn to trends such as looksmaxxing as something they can control", attributing several real-world problems such as an unstable economy and the increase in young men struggling to get into relationships. In some cases, men involved in the practice have reported benefits such as getting a girlfriend, as well as positive affirmation from their peers after improving their looks. Albeit such praise is invariably mixed with critique, which helps maintain a common outlook with less attractive members, who all feel subordinate to the masculine ideal. Several methods of looksmaxxing have been criticized by doctors and dismissed as misinformation, including mewing and bonesmashing. Regarding mewing, researchers have argued that evidence supporting any change in facial structure is lacking. Facial surgeons have criticized bonesmashing saying it includes the risk for fractures, facial misalignment, neurovascular injuries, facial deformity, and alterations in vision.
A variety of esters of nandrolone have been marketed and used medically. The most commonly used esters are nandrolone decanoate and to a lesser extent nandrolone phenylpropionate. Examples of other nandrolone esters that have been marketed and used medically include nandrolone cyclohexylpropionate, nandrolone cypionate, nandrolone hexyloxyphenylpropionate, nandrolone laurate, nandrolone sulfate, and nandrolone undecanoate.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.